Jul 20, 2020 / 12:30PM GMT
Operator
Good morning, and welcome to the Assembly Biosciences conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand the call over to Lauren Glaser, Senior Vice President of Investor Relations and Corporate Affairs for Assembly. Please go ahead.
Lauren Glaser - Assembly Biosciences, Inc. - SVP of IR & Corporate Affairs
Thank you, Bridget. Good morning, and thank you for joining us on such short notice. Today's announcement of our strategic collaboration with BeiGene is an exciting and significant milestone for Assembly. This collaboration provides a strong foundation to accelerate the development in China of our hepatitis B portfolio, which currently consists of 3 clinical stage core inhibitors: ABI-H0731 and ABI-H2158, which are in ongoing Phase II clinical trials, and ABI-H3733, which is in Phase I development.
The press release and the slides we will refer to during the call are available in the News and Events section of our corporate website at
Assembly Biosciences, Inc. - Special Call Transcript
Jul 20, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers